Paralax Life Sciences is an investment and executive consulting group of companies for innovative implementation of medical and life science products and services in Bulgaria

Invested since 2008
Successful companies
Jobs created

Paralax Life Sciences concept was developed in the year 2006 by Dr. Dimiter Georgiev, PhD and Vladislava Georgieva MF, as an investment and executive consulting group of companies for innovative implementation of medical and life science products and services in Bulgaria.

Paralax Life Sciences has crucial expertise in the management, consulting and performing of different activities in the life sciences sector – clinical trials for the development of new and existing pharmaceutical products, collection and storage of cord blood stem cells, introduction in Bulgaria of products for genetic testing, forensics, innovative technologies for smoking cessation and weight management, pharmaco- and cosmetic vigilance, financial analytics for the Bulgarian healthcare and structured funding for innovative projects etc. We help, as well, international life science companies to avoid costly mistakes, to improve their products or services and therefore to improve their chances for market success. Joining efforts with some well positioned NGO’s, we support qualitative and modern patient care.

Paralax Life Sciences will recommend what is required to enter Bulgarian market and devise precise strategies to create, maintain and broaden acceptance, recognition and brand awareness. We not only investigate, analyze and recommend, but we also develop, design and implement a strategic plan in order to pave your road to success. We help clients in the pharmaceutical and biotech industries to define, demonstrate and communicate the safety and value of their products as necessary to meet the diverse expectations of regulators, physicians, and patients. We provide high-quality clinical development services to accelerate and maximize the value of our clients’ investments in the drug development process.

We work, as well, in numerous therapeutic areas: from vaccines to women’s health and have participated in many disease-prevention studies.

Competent consulting on the field of registration of drugs, food supplements, medical devices, advanced medical treatments etc. is a part of the daily life of Paralax Life Sciences company.

Paralax Life Sciences invests own capital in technologies and products for the life science and healthcare markets in Bulgaria and Europe. With our participation at few independent contract research companies we perform clinical trials in human and apply the highest ethical and scientific standard.

Our mission is to

Enable business success in the life sciences in Bulgaria

We accomplish this goal through leadership, collaboration, innovation and advocacy. As an effort to strengthen cross-border collaboration in the life sciences we expand our relations with companies all over Europe.

Like most innovative capital investments, the clinical and life sciences are inherently risky. In today’s uncertain economic climate, many investors are opting to sit out and wait for more certainty in the market before they invest. Nevertheless, the clinical and life sciences market is an area that healthcare-oriented investors may consider targeting more frequently based on recent results. As the worldwide population ages and more people enter their years of greatest healthcare need, demand for new pharmaceuticals, diagnostics, and medical devices has the potential to go higher than we’ve ever seen. That’s why the need for venture capital is greater and one of the ways to generate cash is the partnerships and licensing agreements with larger companies looking to expand their product pipelines.

Paralax Life Sciences is focused on helping its customers cultivate business growth in the global clinic & life science marketplace through the development, marketing and distribution of high quality solutions. We offer an experienced leadership team and a dynamic and diverse portfolio to demonstrate our customers’ success.

Our mission is to provide a comprehensive range of integrated development services of superior value for our customers, enhancing the regulatory acceptance, the speed to market and the return on investment of their products. We work to improve public health and well-being and our core values are:

  • Customer focus
  • Demand of total quality
  • Value for the individual
  • Shareholder value
  • Integrity at all levels of execution

Paralax Life Sciences approach focuses on the risk and return characteristics of an investment rather than those criteria that are often used to define venture investments (e.g. sector, therapeutic area, stage of asset development). Hence, we invest in both early stage and late stage companies, platforms and products, discovery and development. However, our main competence are start-ups.

Many factors contribute to the investment attractions of clinic & life science companies:

  • There is a considerable unsatisfied demand for healthcare products, driven by increasing consumer expectations and demand for life-style therapeutics.
  • The population is ageing, driving up healthcare expenditure per capita.
  • There is a lack of safe, effective treatments for many diseases. Furthermore, for some well-tested therapies, treatment rates are low.
  • Healthcare costs are increasingly of concern to payers. Innovation in healthcare is the best hope for improving productivity of healthcare delivery.

When it comes to life science productivity, Europe has four of the five top ranked countries in this area. Europe is also a major centre for pharmaceutical development and is home to four of the world’s top five pharmaceutical companies. Successful companies can be built upon Europe’s research base to generate attractive returns for investors. Clinic and life science technologies are global businesses. Regardless of location, companies must strive to attain the standards of, and be benchmarked against, the best competition globally.

Dimitar B. GeorgievMD, PhD

Founder & CEO

Paralax Life Sciences invests in different areas of the clinical and life sciences including pharmaceuticals, diagnostics and health technologies. There are no fixed criteria for investment size but we expect to make aggregate investments of minimum € 50 000 in each of our portfolio companies. We will consider investing companies based anywhere in the world but we are particularly focused on Europe.

For more information on any of our portfolio companies, please click on the relevant link below:

Medical clinic Ascendent
NM Genomix / Prenatest
CCDRD | Milray | ProDuct | MilReit
SGP Biodynamicsdigene HPV test
Pharmalex Bulgaria
Life Science Projects
Institute for Medical Research

Via subsidiaries and related parties Paralax Life Sciences holds shares of:

Glaxo Smith Kline

Should you be interested in meeting the MVM team to discuss your business and its plans for the future please contact us.

Paralax Life Sciences has a broad and efficient network in the life science community in Bulgaria and also excellent communications with prominent financial and regulatory institutions in the country. The staff of the subsidiaries of Paralax Life in Bulgaria consists predominantly of intelligent, highly-motivated people, dedicated to work together as a team improving the human condition through innovation in the clinic and life sciences, but also basic research. Our team has been involved in the creation, financing and management of more than 10 life science companies and has significant experience in research and development, consulting, finance and operational management. The exceptional talent, skill, and passion of our employees are the key to Paralax Life Sciences’s excellence, success and value.

The founders of Paralax Life Sciences have supported several successful marketing campaigns for ethical and OTC medications, as also effective introductions of diagnostic tests and medical devices on the Bulgarian market. Some patient loyalty programs have been awarded on international patient’s forums.


The latest buzz in life science as we saw it